Drug Profile
Molindone - Supernus Pharmaceuticals
Alternative Names: AFX 2201; EN-1733A; Molindone hydrochloride; Molindone XR; SPN-810; SPN-810M; ZalvariLatest Information Update: 11 Apr 2023
Price :
$50
*
At a glance
- Originator Afecta Pharmaceuticals
- Developer Supernus Pharmaceuticals
- Class Antipsychotics; Behavioural disorder therapies; Indoles; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Attention-deficit hyperactivity disorder
Most Recent Events
- 11 Apr 2023 Supernus in licensed Molidone from Afecta Pharmaceuticals before April 2023 (Afecta Pharmaceuticals, April 2023)
- 22 Oct 2020 Supernus Pharmaceuticals terminates a phase III trial in Attention deficit hyperactivity disorder in USA (NCT03597503)
- 01 Apr 2020 Supernus Pharmaceuticals completes the phase III extension CHIME 4 trial in Attention deficit hyperactivity disorder (In children, Adjunctive treatment) in USA (NCT02691182)